Tagged with IoT

Brazil Luciano Finardi, general manager of Celgene Brazil, describes the unrivalled commitment of the company to Brazilian patients and documents the remarkable dedication of Celgene to registering its flagship product in Brazil, as well as the company’s willingness to cope with the country’s unpredictability while establishing its operation in Brazil. Celgene…

Brazil Mauro Loch, general manager of Amgen Brazil, documents the eye-catching turnaround of the affiliate since the beginning of his tenure and provides insights into the company’s unique positioning in Brazil, the outstanding performance of recently launched products, as well as his main priorities to further increase access to Amgen’s life-changing…

Tunisia Hammadi Ayadi, CEO of Sidi Thabet BiotechPole, proudly introduces the launch of the site’s incubator and announces the soon-to-come opening of the company cluster. This will provide a platform for the fusion of theoretical research and technical knowhow and aid the development of the first biotech drug made in Tunisia…

Bulgaria Krassimira Chemishanska, country director at Amgen Bulgaria, showcases the role of innovative players in the country, the importance of moving towards a value-based assessment system, and how Amgen has performed since its entrance to the Bulgarian market back in 2009. You opened the Bulgarian affiliate back in 2009. How challenging…

Switzerland Giacomo Di Nepi, CEO of innovative Swiss specialty pharma outfit Polyphor, discusses his decision to join the company in 2016, his main priorities, and the potential impact of an IPO in the next two years. Having previously held senior leadership responsibilities with Takeda and Novartis, spending time as partner at…

Canada Andrew Casey, President and CEO of BIOTECanada, the national biotech association, provides an update on the Canadian biotech landscape, the strength of the Canadian R&D ecosystem, the growing investor community (both Canadian and foreign) looking to Canada as an untapped land of opportunities, and his hope to position Canada as…

Tunisia Hechmi Louzir, general manager of the Institut Pasteur in Tunis (IPT), details the crucial role that the IPT plays in the development of the Tunisian health sector, his wide-ranging responsibilities as general manager, the increasing importance of building new partnerships between the private and public sectors, and the Institute’s ambition…

Canada Peter Brenders, general manager of Sanofi Genzyme Canada, highlights the strategic significance of the Canadian affiliate, which has seen double-digit growth every quarter for the past five and a half years; the challenges it faces within Canada’s market access environment; and the personal motivation driving him after three decades in…

Tunisia The long-awaited conference marking the launch of the company cluster of Sidi Thabet (a city in the governorate of Ariana, 20 minutes from Tunis airport) took place on September 28th 2017 at the Tunis export centre (CEPEX) and revolved around the theme: “Sidi Thabet BioTechpole: serving innovation in the pharmaceutical…

Tunisia Hatem Hachicha is Pfizer’s former manager for Tunisia, Libya and French-speaking African countries. He believes Tunisia’s pharmaceutical industry development will be achieved through internationalization and a shift towards biosimilars drugs. Co-founder of SEPHIRE and an active member of the Tunisian healthcare community, he stresses that one of the challenges in…

Austria Dr. Daniel Wallerstorfer, CEO and founder of Novogenia, a vibrant Austrian genetics company, discusses founding his own company and the innovative services Novogenia provides to ensure genetics are a staple part of global preventative measures. He also provides an insight into the future of genetic analysis and the positive overall…

Colombia Newar Giraldo, General Manager of Humax in Colombia, discusses the company’s role in countering monopolistic situations, their recent focus on OTC medicines, as well as their selective internationalization strategy based on regulatory fit, and his intention to enter the nanotechnology and biosimilar sectors.  Could you introduce our readers to the…